摘要
目的:观察依达拉奉联合尤瑞克林治疗急性脑梗死的临床疗效。方法:20例急性脑梗塞患者随机分为治疗组和对照组,每组10例患者。两组均予常规治疗,在此基础上治疗组加用依达拉奉联合尤瑞克林,对照组单用依达拉奉治疗;治疗14d后比较两组的临床疗效和神经功能缺损评分。结果:治疗后治疗组的临床疗效、NIHSS评分明显优于对照组,两组比较差异有统计学意义(P<0.01,P<0.05),且无明显不良反应。结论:依达拉奉联合尤瑞克林治疗急性脑梗死能够明显提高疗效,且无明显不良反应,值得临床推广应用。
To observe the clinical effects of edaravone combined minary kallidinogenase in trealment of acute cerebral infarction.Methods：20 acute cerebral infarction patients were randomly divided into trealment group and control group （n=lO）.Patients in these 2 groups were all given conventional therapy;moreover, the patients in treatment group were treated with edaravone combined urinary kallidinogenase,while patients in control group were only given edaravone. The clinical effects and NIHSS of patients in 2 groups were compared after 14-day Ireafing.Results：Afler treatment,the clinical effects and NIHSS of treatment group were obviously better than control group （P〈 0.01,P〈 0.05）, and no obvious adverse reactions.Conclusions：Treating acute cerebral infarction with edaravone combined urinary kallidinogenase can improve clinical effects significantly and no obvious adverse reactions;so it is worthy of applying in clinic.
出处
《承德医学院学报》
2012年第1期34-35,共2页
Journal of Chengde Medical University
关键词
依达拉奉
尤瑞克林
急性脑梗死
疗效
Edamvone
Urinary kallidinogenase
Acute cerebral infarction
Clinical effect
